Esophageal atresia is a rare, congenital (present at birth) disorder of the digestive system in which the esophagus, the tube that normally carries food from the mouth to the stomach, does not connect ...

Subepithelial lesions (SLEs) are often detected incidentally during endoscopic examination. They represent a heterogeneous group of lesions including non-neoplastic and neoplastic lesion, the most ...

This is the first study to qualitatively explore the acceptability of the Cytosponge test among members of the public who may be at increased risk for Barrett's oesophagus. The sample was diverse in ...

Julie Thompson, information manager at the digestive system charity Guts UK, says: “Oesophageal cancer can be difficult to spot, as it might not cause any symptoms until it causes an obstruction of ...

and histology-guided surveillance and treatment of individuals with Barrett's oesophagus, have considerable limitations. Barrett's oesophagus rarely progresses to oesophageal adenocarcinoma ...

Finding genetic, esophageal impedance signs or other biomarkers that can reliably identify the acute and recurrent stages of the disease are still an unmet need. In the meantime concordance on ...

This disease affects the oesophagus - the tube connecting your mouth to your stomach. It is an especially dangerous form of cancer, ranking as the 14th most common in the UK but causing the ...

Background While p53 mutations occur early in Barrett’s oesophagus (BE) progression to oesophageal adenocarcinoma (EAC), their role in gastric cardia stem cells remains unclear. Objective This study ...

Chi-Yang Chang; Michael B Cook; Yi-Chia Lee; Jaw-Town Lin; Takafumi Ando; Shobna Bhatia; Wong-Ho Chow; Emad M El-Omar; Hidemi Goto; Yang-Qing Li; Kenneth McColl; Nageshwar Reddy; Poong-Lyul Rhee ...

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up ...

Chemoimmunotherapy plus radiotherapy in advanced esophageal squamous-cell carcinoma. Pembro: pembrolizumab, mo: month. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...